FDA Approved: ADALIMUMAB-RYVK — Supplemental Application (Quallent Pharmaceuticals Health LLC)

View source ↗

Summary

The FDA approved a supplemental application for ADALIMUMAB-RYVK, a biosimilar to adalimumab, submitted by Quallent Pharmaceuticals Health LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis
• Crohn Disease
• Hidradenitis Suppurativa
• Juvenile Idiopathic Arthritis
• Plaque Psoriasis
• Psoriatic Arthritis
• Rheumatoid Arthritis
• Ulcerative Colitis

Drugs mentioned

• ADALIMUMAB-RYVK (adalimumab)

Snippet

SUPPL AP for ADALIMUMAB-RYVK (ADALIMUMAB-RYVK)